Biomarkers for the early detection of pancreatic cancer are urgently needed. However, individual molecules with the sensitivity and specificity needed for population-based screening have not been discovered. CA-19-9 has been studied extensively and yet has failed to demonstrate the predictive value necessary for early detection and diagnosis. Although many platforms, including proteomic, genomic and transcriptomic approaches have been utilized and biomarker candidates identified, no one platform or molecule has been successfully validated in large population screens. As a part of the National Cancer Institute Early Detection Research Network, we are taking a targeted approach to assemble a panel of biomarker candidates, given that no one biomarker has shown promise for early detection. We hypothesize that a panel of early detection biomarkers for pancreatic cancer could be discovered by the identification of the earliest genetic pathways aberrant in pancreatic cancer. We furthermore hypothesize that genetic pathways involving tumor suppressor genes with loss of function mutations/deletions and dominantly activated/amplified/over expressed oncogenes are critical determinants in the development of the early phases of pancreatic neoplasia. Project 1 is utilizing a functional genomics approach toward biomarker discovery and is targeting the chromosome 3p12 pathway to tumorigenesis in pancreatic cancer. Three separate expression platforms have been utilized to develop a panel of genes differentially expressed in pancreatic tumor/normal samples and which represent potential genes in the 3p pathway as well as a novel tumor suppressor/polarity regulator DEAR1 is being characterized as a pancreatic cancer biomarker. Project 2 is examining copy number altered genes and miRNAs as early detection biomarkers utilizing an integrated functional genomics and pathway network analysis approach. Project 3 is examining a panel of 1,536 SNPs and relevant covariates in 1000 pancreatic cancer patients to develop a risk model to identify those individuals most likely to develop pancreatic cancer at an early age and could be stratified for screening using biomarker panels developed in projects one and two.

Public Health Relevance

Pancreatic cancer is the 4^ leading cause of cancer mortality in the United States. It is also a disease of poor prognosis for which the 5-year survival is less than 5%. Because pancreatic cancer is such a devastating disease, it is critical to be able to detect it early, however, there are currently no viable biomarkers that have been proposed for general population screening. Our BDL associated with the NCI EDRN is generating a panel of biomarkers and a risk assessment tool for early detection.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-C (M1))
Program Officer
Rinaudo, Jo Ann S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Other Domestic Higher Education
United States
Zip Code
Wang, Jin; Chen, Jinyun; Sen, Subrata (2016) MicroRNA as Biomarkers and Diagnostics. J Cell Physiol 231:25-30
Wang, Jin; Paris, Pamela L; Chen, Jinyun et al. (2015) Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions. Cancer Lett 356:404-9
Smith, Jill P; Whitcomb, David C; Matters, Gail L et al. (2015) Distribution of cholecystokinin-B receptor genotype between patients with pancreatic cancer and controls and its impact on survival. Pancreas 44:236-42
Wang, Jin; Yin, Hailin; Panandikar, Ashwini et al. (2015) Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug. Int J Oncol 47:782-90
Wang, Jin; Zhang, Ke-Yong; Liu, Song-Mei et al. (2014) Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules 19:1912-38
Liu, Qian; Chen, Jinyun; Wang, Jin et al. (2014) Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma. Mol Carcinog 53:711-21
Chen, Nanyue; Balasenthil, Seetharaman; Reuther, Jacquelyn et al. (2014) DEAR1, a novel tumor suppressor that regulates cell polarity and epithelial plasticity. Cancer Res 74:5683-9
Qi, Jia-Hui; Wang, Jin; Chen, Jinyun et al. (2014) High-resolution melting analysis reveals genetic polymorphisms in microRNAs confer hepatocellular carcinoma risk in Chinese patients. BMC Cancer 14:643
Chen, Nanyue; Balasenthil, Seetharaman; Reuther, Jacquelyn et al. (2013) DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-*-driven epithelial-mesenchymal transition. Cancer Discov 3:1172-89
Qi, J; Wang, J; Katayama, H et al. (2013) Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma 60:135-42

Showing the most recent 10 out of 21 publications